{
    "nctId": "NCT02428114",
    "briefTitle": "A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)",
    "officialTitle": "A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)",
    "overallStatus": "COMPLETED",
    "conditions": "Early Stage Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 142,
    "primaryOutcomeMeasure": "Feasibility of performing this study will be measured with composite endpoints: physician engagement, time for local or provincial research ethics approval, accrual rates, and patient/physician compliance.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed primary breast cancer\n* Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy\n* \u226519 years of age\n* Able to provide verbal consent\n\nExclusion Criteria:\n\n* Contraindication to Filgrastim",
    "sex": "ALL",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}